BioVie Inc. BIVI
As ofNov 19, 2026, 10:02 AM EST
- YTD
- -20.69%
- 1 year
- -32.85%
5D -0.2317 (-19.15%)
- Market cap
- 9.87M
- EPS (ttm)
- -2.85
- Shares out
- 17.77M
- Forward P/E
- -0.49
- YTD return
- -20.69%
- 1-year return
- -32.85%
- 50-day average
- 2.66
- 200-day average
- 3.68
- Volume
- 38.96K
- Avg volume
- 1.64M
- Open
- 0.9449
- Previous close
- 0.9428
- Day's range
- 0.9102 – 0.9449
- 52-week range
- 0.82 – 3.79
- Beta
- 0.90
- Price target
- 5.00 (+443.5%)
Key statistics
- Enterprise value
- 7.49M
- Price / book
- 0.86
- Free cash flow
- -18.78M
- Total cash
- 23.84M
- Total debt
- 6.11M
- Return on equity
- -208.26%
- Short % of float
- 12.52%
Fundamental scorecard
5 of 25 checks passed on BIVI’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.70 | — | — |
| Sep 30, 2024 | Jun 1, 2024 | 0.00 | -6.60 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -2.00 | — | — |
| Feb 12, 2024 | Dec 1, 2023 | -3.20 | -2.20 | +1.00 | +31.25% |
| Nov 8, 2023 | Sep 1, 2023 | 0.00 | -2.90 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 1, 2024 | ThinkEquity | init | — | Buy |
| Nov 30, 2023 | Oppenheimer | main | Outperform | Outperform |
| Aug 22, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Jul 18, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| May 17, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| May 17, 2023 | Oppenheimer | reit | Outperform | Outperform |
About BioVie Inc.
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bioviepharma.com
News
BioVie Presents New Biomarker Data Highlighting Biomarker-Defined Endotypes and Neuropeptide Y Response to Bezisterim at the 4th Long COVID International Conference 2026 BioVie Presents New Biomarker Data From ADDRESS-LC Trial Of Bezisterim In Long COVID; Analyses Suggest Single Efficacy Endpoint May Not Adequately Capture Clinically Meaningful Response To Therapeutic Intervention Across Biological Diversity Of Long Covid
12 Health Care Stocks Moving In Wednesday's Intraday Session BioVie Announces $4.74M Registered Direct Offering And Concurrent Private Placement
12 Health Care Stocks Moving In Tuesday's Intraday Session BioVie Invited To Present Late-Breaking Oral Presentation At The 4th Long Covid International Conference, November 12-13
12 Health Care Stocks Moving In Tuesday's Intraday Session BioVie Reports Data From Phase 2 ADDRESS-LC Trial Of Bezisterim At 151st Annual Meeting Of American Neurological Association
Your note
Sign in to keep a note on BIVI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERMAN RICHARD JAY | Director | Stock Award(Grant) | Nov 8, 2023 | 69,235 |
| DO CUONG VIET | Chief Executive Officer | Stock Award(Grant) | Jun 23, 2024 | 0 |
| GORLIN STEVEN | Director | Sale | Nov 30, 2023 | 46,358 |
| HARIRI ROBERT J | Director | Stock Award(Grant) | Nov 8, 2023 | 42,254 |
| KIM JOANNE WENDY | Chief Financial Officer | Stock Award(Grant) | Jun 23, 2024 | 93,940 |
| PALUMBO JOSEPH M | Officer | Stock Award(Grant) | Jun 23, 2024 | 119,196 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 0.32% | 56,837 | 122.20K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.21% | 38,174 | 82.07K | Sep 29, 2024 |
| Zullo Investment Group, Inc. | 0.14% | 25,000 | 53.75K | Sep 29, 2024 |
| Cerity Partners LLC | 0.10% | 17,230 | 37.04K | Sep 29, 2024 |
| United Capital Management of KS, Inc. | 0.06% | 10,000 | 21.50K | Sep 29, 2024 |
| National Bank of Canada/FI | 0.02% | 4,300 | 9.24K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.23% | 41,509 | 89.24K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.12% | 21,816 | 46.90K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.08% | 14,764 | 31.74K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.03% | 5,158 | 11.09K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.01% | 1,855 | 3.99K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 2,295 | 4.93K | Oct 30, 2024 |
